Hindustan bio sciences Limited has filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reporting the acquisition of shares by Bosco Armando Menezes and Emily Bosco Menezes on January 23, 2026.

Share Acquisition Details

The acquisition involved the purchase of 15,000 shares through open market transactions on January 22, 2026. The acquirers, Bosco Armando Menezes and Emily Bosco Menezes, are not part of the promoter group of the company.

Shareholding Pattern Changes

Prior to this acquisition, the combined holding of both acquirers stood at 5,10,000 shares, representing 4.98% of the total voting capital. The recent purchase has increased their combined shareholding to 5,25,000 shares, representing 5.12% of the company's total voting capital.

Individual Shareholding Breakdown

The disclosure reveals the individual shareholding pattern of both acquirers. Bosco Armando Menezes and Emily Bosco Menezes each held 2,55,000 shares before the acquisition. After the purchase, their combined voting rights increased to 2,70,000 shares, while maintaining 2,55,000 shares in encumbered form.

Company Capital Structure

The company's equity share capital remains unchanged following this transaction. Hindustan Bio Sciences Limited maintains its equity share capital at Rs.2,05,01,600, consisting of 1,02,50,800 equity shares of Rs.2 each. The company's shares are listed on BSE Limited.

The disclosure was signed by J V R Mohan Raju, Managing Director of Hindustan Bio Sciences Limited, and filed with BSE Limited on January 23, 2026, in compliance with SEBI regulations for substantial acquisition of shares.

Hindustan Bio Sciences Ltd. has announced its financial results for the first quarter, along with key management changes. The company's board meeting, held on July 31, addressed several important matters, including financial performance and corporate governance.

Q1 Financial Performance

For the quarter ended June 30, Hindustan Bio Sciences reported:

The company's revenue from operations for Q1 FY2026 stood at Rs. 32.19 lakhs, showing a decrease compared to both the previous quarter and the same quarter last year. Despite the revenue decline, Hindustan Bio Sciences managed to maintain profitability, reporting a profit of Rs. 1.40 lakhs for the quarter.

Management Changes

In a significant development, the company announced changes in its key managerial personnel:

1. Resignation of Company Secretary: Mr. Devanshu Ravinder Dange has resigned from his position as Company Secretary, Compliance Officer, and Key Managerial Personnel, effective from the closing business hours of July 31. Mr. Dange cited personal reasons for his departure.

2. New Appointment: Mr. Shailendra Vyas has been appointed as the new Company Secretary, Key Managerial Personnel, and Compliance Officer, effective August 1. Mr. Vyas is an Associate Member of the Institute of Company Secretaries of India (ICSI) and holds a Bachelor's degree in Commerce (Computer Applications) from Telangana University and a Bachelor's degree in Law (LL.B.) from Osmania University.

Corporate Governance and Compliance

The board meeting also addressed several corporate governance matters:

• Approval of the notice for the 33rd Annual General Meeting (AGM), along with the Directors' report and Corporate Governance report for the financial year ended March 31.
• Adoption of the Secretarial Audit Report for the Financial Year 2024-25, issued by Mr. VBSS Prasad, Practicing Company Secretary.
• Appointment of Mr. VBSS Prasad as the scrutinizer for conducting e-voting at the upcoming AGM.

Looking Ahead

While the company faced a decline in revenue compared to previous periods, it has maintained profitability. The management changes and focus on corporate governance indicate Hindustan Bio Sciences' commitment to strengthening its organizational structure and compliance practices.

Investors and stakeholders will be keenly watching how these changes and the company's strategies impact its performance in the coming quarters.